The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
作者： Eric Van Cutsem , Karen Geboes
DOI: 10.1016/J.BPG.2007.10.020
关键词: Capecitabine 、 Colorectal cancer 、 Oncology 、 Epidermal growth factor receptor 、 Medicine 、 Irinotecan 、 Cetuximab 、 Panitumumab 、 Internal medicine 、 Bevacizumab 、 Oxaliplatin
摘要: The management of patients with metastatic colorectal cancer (CRC) has changed dramatically over the last five years, increasing chances prolonged survival. development new drugs contributed to better outcome cancer. Until mid-1990s only available drug, limited activity in CRC, was 5-fluorouracil (5-FU). cytotoxic agents irinotecan, oxaliplatin and capecitabine monoclonal antibodies against vascular endothelial growth factor (VEGF) bevacizumab epidermal receptor (EGFR) cetuximab panitumumab have clearly increased therapeutic options improved for However, their introduction also raises many questions challenges.
elsevier.com
sci-hub.se 参考文章(98)
A F Sobrero, C Aschele, J R Bertino, Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. Journal of Clinical Oncology. ,vol. 15, pp. 368- 381 ,(1997) , 10.1200/JCO.1997.15.1.368
Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, Ralf Wong, Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study Journal of Clinical Oncology. ,vol. 19, pp. 2282- 2292 ,(2001) , 10.1200/JCO.2001.19.8.2282
Eric Van Cutsem, Michael Findlay, Bruno Osterwalder, Walter Kocha, David Dalley, Richard Pazdur, Jim Cassidy, Luc Dirix, Chris Twelves, David Allman, Jean-Francois Seitz, Jürgen Schölmerich, Hans Ulrich Burger, Jaap Verweij, Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study Journal of Clinical Oncology. ,vol. 18, pp. 1337- 1345 ,(2000) , 10.1200/JCO.2000.18.6.1337
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
Emilio Bajetta, Maria Di Bartolomeo, Luigi Mariani, Antonio Cassata, Salvatore Artale, Sergio Frustaci, Graziella Pinotti, Andrea Bonetti, Ignazio Carreca, Guido Biasco, Luigi Bonaglia, Giovanni Marini, Antonio Iannelli, Diego Cortinovis, Ermina Ferrario, Elena Beretta, Antonio Lambiase, Roberto Buzzoni, Italian Trials in Medical Oncology (ITMO) Group, Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer. ,vol. 100, pp. 279- 287 ,(2004) , 10.1002/CNCR.11910
W Scheithauer, H Rosen, G V Kornek, C Sebesta, D Depisch, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. ,vol. 306, pp. 752- 755 ,(1993) , 10.1136/BMJ.306.6880.752
R.G. Amado, M. Wolf, D. Freeman, M. Peeters, E. Van Cutsem, S. Siena, S. Suggs, S. Patterson, D. Chang, 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy Ejc Supplements. ,vol. 5, pp. 8- ,(2007) , 10.1016/S1359-6349(07)70100-3
Napoleone Ferrara, None, VEGF as a Therapeutic Target in Cancer Oncology. ,vol. 69, pp. 11- 16 ,(2005) , 10.1159/000088479
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066